glp-1 mash Resmetirom and agonists for MASH: complementary rather than exclusive The Interplay Between GLP-1-Based Therapies,
Description
While early results are promising, further research is necessary to determine their long-term efficacy in managing HS
and Berger N
Researchers also found the proportion of users of GLP-1 medications without FDA-approved indications rose from 0.21% in 2019 to 0.37% in 2023
Where there is that much money and that much consumer anxiety, marketing tends to outrun evidence
Authors Note This piece builds on my ongoing coverage of the intersection of health, technology, and capital from the GLP-1 economy reshaping American medicine to the rise of longevity as a new asset class
A., Skene, R
